Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127414771 | 12741477 | 1 | I | 20160823 | 20160914 | 20160914 | EXP | US-ROCHE-1829838 | ROCHE | 59.00 | YR | F | Y | 108.40000 | KG | 20160914 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127414771 | 12741477 | 1 | PS | Bevacizumab | BEVACIZUMAB | 1 | Unknown | 1270 MG TO 2380 MG | U | 125085 | |||||||||
| 127414771 | 12741477 | 2 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Unknown | 60 MG TO 80 MG | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127414771 | 12741477 | 1 | Carcinoid tumour |
| 127414771 | 12741477 | 2 | Carcinoid tumour |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127414771 | 12741477 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127414771 | 12741477 | Blood bilirubin increased | |
| 127414771 | 12741477 | Fatigue | |
| 127414771 | 12741477 | Hyperglycaemia | |
| 127414771 | 12741477 | Hyponatraemia | |
| 127414771 | 12741477 | Hypophosphataemia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |